Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine combination therapy versus camostat combination versus no treatment in hospitalized adults with mild-risk or moderate COVID-19
MOH_2020-04-20_008862Phase 3Recruiting
- Sponsor
- דר' יצחק לוי
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine, azithromycin and camostat mesilate in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by דר' יצחק לוי. Primary endpoints: Clinical status at day 7 and Positive viral test in secretions at day 7. Started Apr 2020; status: recruiting.
02
Drugs
hydroxychloroquineazithromycincamostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-04-20_008862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-20_008862.